Dalegrave Daniele, Silva Rafael Lockshin, Becker Maicon, Gehrke Lísia Varella, Friedman Gilberto
Central Intensive Care Unit, ComplexoHospitalar Santa Casa - Porto Alegre (RS), Brazil.
Rev Bras Ter Intensiva. 2012 Dec;24(4):362-8. doi: 10.1590/s0103-507x2012000400012.
To evaluate if cortisol responses to 250 µg of intravenously administered adrenocorticotropic hormone are related to disease severity and, hence, mortality.
This is a retrospective study in a medical-surgical intensive care unit of a university hospital. We studied 69 consecutive patients with septic shock over a 1-yr period; these patients underwent a short 250-µg adrenocorticotropic hormone test because they exhibited >6 hours of progressive hemodynamic instability requiring repeated fluid challenges and vasopressor treatment to maintain blood pressure. The test was performed by intravenously injecting 250 µg of synthetic adrenocorticotropic hormone and measuring cortisol immediately before injection, 30 minutes post-injection and 60 minutes post-injection.
The mean APACHE II score was 22±7. The intensive care unit mortality rate at day 28 was 55%. Median baseline cortisol levels (19 [11-27] µg/dL versus 24 [18-34] µg/dL, p=0.047) and median baseline cortisol/albumin ratios (7.6 [4.6-12.3] versus 13.9 [8.8-18.5]; p=0.01) were lower in survivors than in non-survivors. Responders and non-responders had similar baseline clinical data and outcomes. The variables that were significantly correlated with outcome based on the area under the ROC curves (AUC) were APACHE II (AUC=0.67 [0.535 to 0.781]), baseline cortisol (µg/dl) (AUC=0.662 [0.536 to 0.773], peak cortisol (µg/dl) (AUC=0.642 [0.515 to 0.755]) and baseline cortisol/albumin (AUC=0.75 [0.621 to 0.849]).
Increased basal cortisol is associated with mortality and disease severity. Cortisol responses upon adrenocorticotropic hormone stimulation were not related to outcome. The cortisol/albumin ratio does not predict unfavorable outcomes better than total cortisol levels or help to improve the accuracy of the adrenocorticotropic hormone test.
评估静脉注射250微克促肾上腺皮质激素后皮质醇反应是否与疾病严重程度相关,进而与死亡率相关。
这是一项在大学医院内科-外科重症监护病房进行的回顾性研究。我们在1年期间研究了69例连续的感染性休克患者;这些患者接受了简短的250微克促肾上腺皮质激素测试,因为他们出现了超过6小时的进行性血流动力学不稳定,需要反复进行液体复苏和血管升压药治疗以维持血压。该测试通过静脉注射250微克合成促肾上腺皮质激素并在注射前、注射后30分钟和注射后60分钟测量皮质醇来进行。
急性生理与慢性健康状况评分系统(APACHE II)的平均得分为22±7。第28天的重症监护病房死亡率为55%。幸存者的基线皮质醇水平中位数(19 [11 - 27]微克/分升对24 [18 - 34]微克/分升,p = 0.047)和基线皮质醇/白蛋白比值中位数(7.6 [4.6 - 12.3]对13.9 [8.8 - 18.5];p = 0.01)低于非幸存者。反应者和无反应者具有相似的基线临床数据和结局。基于ROC曲线下面积(AUC)与结局显著相关的变量包括APACHE II(AUC = 0.67 [0.535至0.781])、基线皮质醇(微克/分升)(AUC = 0.662 [0.536至0.773])、皮质醇峰值(微克/分升)(AUC = 0.642 [0.515至0.755])和基线皮质醇/白蛋白(AUC = 0.75 [0.621至0.849])。
基础皮质醇升高与死亡率和疾病严重程度相关。促肾上腺皮质激素刺激后的皮质醇反应与结局无关。皮质醇/白蛋白比值在预测不良结局方面并不比总皮质醇水平更好,也无助于提高促肾上腺皮质激素测试的准确性。